Home / Health / Telemedicine Firm Fights License Revocation

Telemedicine Firm Fights License Revocation

Summary

  • FDCA canceled a company's license for selling Mounjaro without a specialist.
  • The company alleges arbitrary decision-making and procedural violations.
  • The dispute involves telemedicine sales and prescription validity.

A Vadodara-based telemedicine company has escalated its dispute to the Gujarat High Court after its license to sell medicines was revoked by the Food and Drugs Control Administration (FDCA). The license cancellation, effective April 2, followed a show-cause notice issued in March. The company's subsequent appeal was rejected on July 27, leading it to petition the high court, alleging procedural irregularities and a failure to consider its explanations, which it deems "arbitrary, irrational, and passed in violation of principles of natural justice."

Authorities cited insufficient traceability due to incomplete doctor and patient addresses on sales bills. They also highlighted that Mounjaro, an obesity drug, is labeled for endocrinologist or internal medicine specialist prescription only. The FDCA also raised concerns that the company allegedly dispatched the drug, administered subcutaneously, via courier to patients without a doctor's direct supervision, having sold approximately 2,600 injections in a year. The appellate authority acknowledged a "grey area" in telemedicine drug dispensing but maintained the cancellation, stressing the moral duty to prevent public health harm.

The company's petition asserts that its detailed procedures for sales, prescriptions, and deliveries were disregarded. It contends the cancellation relied on grounds not initially specified in the show-cause notice, denying it a fair opportunity to respond. The firm further questions the authorities' contradictory stance on telemedicine guidelines and the insistence on face-to-face consultations. It also challenges the eligibility of general medicine practitioners to prescribe Mounjaro, referencing the National Medical Commission's curriculum. Justice Aniruddha Mayee has issued a notice to the authorities, seeking a response on staying coercive actions and allowing the company to resume operations, with the next hearing scheduled for November 23.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.

Read more news on

Property Code: 5571